Antitrust, Regulation and the Next World Order

Cristina Caffarra’s recent conference has generated extensive public debate. In a new article, our Executive Editor Teddy Downey discusses the event’s impact on antitrust discourse in Europe and the US.

Read the Article

Conference Replay

Antitrust, Regulation, and the Next World Order

Speakers from around the world took the stage at the 2024 “Antitrust, Regulation and the Next World Order” conference in Brussels, organized and chaired by Cristina Caffarra, with support from The Capitol Forum. 

Watch the Sessions

Discover the Benefits of a Subscription

Our content provides subscribers with unique insight and breaking news regarding the most complex mergers and regulatory situations around the world.

Inquire

The Capitol Forum Advantage

Our work combines cutting edge breaking news with in-depth analysis to better inform readers how policy and regulation affects market competition.

Learn More

The Capitol Forum Community

Our editorial team reconstructs the policy process to yield market insight for a community of subscribers including government regulators, lawyers, investors, and non-profits.

Learn More

FEATURED ARTICLES

View all

RECENT PODCASTS

View all

ABOUT THE CAPITOL FORUM

We are an investigative news organization providing our subscribers with detail-oriented reporting on antitrust, merger control, corporate investigations, and energy issues.

COVERAGE

TESTIMONIALS

Karl A. Racine - Former D.C. Attorney General

“I appreciate the helpful work done by The Capitol Forum. It’s one of the sources I turn to for information about what activity is out there not only in the antitrust space, but also in the consumer protection world.”

Melissa H. Maxman - Partner, Cohen & Gresser

“I have become an avid reader of The Capitol Forum because it provides timely in-depth news and analysis of the myriad legal, business, legislative and political factors affecting business developments. I always come away with fresh perspectives that help me advise my clients about current issues.”

Barry Nigro - Partner and Antitrust Chair, Fried Frank

“The Capitol Forum’s news and analysis is spot on and reflects a perfect mix of investigative reporting, independent research, and expert opinion.”

Bert Foer - Former President, American Antitrust Institute

“The Capitol Forum provides an always interesting and sometimes surprising look under the hood about pending antitrust activities.”

Barry Lynnn - Citizens Against Monopoly

“The Capitol Forum is the only team covering this incredibly important beat. Better yet, their work is deeply intelligent, influential, and almost always right.”

Allen Grunes - Co-Founder, Konkurrenz Group

“The Capitol Forum consistently provides timely and sophisticated news and analysis of important M & A transactions. It’s the real deal!”

David Witkin - Beryl Capital Management

“The Capitol Forum has been an indispensable resource for me in analyzing regulatory risk affecting companies in my portfolio or watch list.”

RECENT ARTICLES | EDITOR'S PICKS

View all

RESOURCES

View all

AI Act DSA and DMA Implementation

Jan 31, 2024

Roberto Viola, Director General of DG Connect, speaks at the 2024 “Antitrust, Regulation and the Next World Order” conference in Brussels, organized and chaired by Cristina Caffarra, with support...
Thank you for subscribing to our newsletter

SPECIAL REPORTS

View all

SPECIAL REPORT: Coordination Out Loud

Analysis of select corporate transcripts through the lens of Joseph Harrington’s landmark paper, “Collusion in Plain Sight: Firms’ use of Public Announcements to Restrain Competition.”

Sep 07, 2023 Read Now >

SPECIAL REPORT: Johnson & Johnson’s Remicade

Get an inside view of the biologics market, where rebate schemes appear to drive market share. You’ll learn how a complex system supports sluggish biosimilar uptake and other types of anticompetitive conduct. 

Sep 05, 2023 Read Now >

SPECIAL REPORT: Exclusive Drug Dealing

The Capitol Forum has recently published a special report with an extract of reporting that has been done analyzing price, market share and generic formulary exclusion data to spot anticompetitive conduct.

May 11, 2023 Read Now >